{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:00:23Z","timestamp":1792000823960,"version":"4.4.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Limited data exist on the natural history and treatment persistence in ulcerative colitis (UC) patients on 5-aminosalicylic acid (5-ASA) in the era of biologic agents and small molecules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study utilizing the US Collaborative Network in patients with UC who were initiated on 5-ASA between 2015 and 2019. The 1-, 3-, and 5-year incidence rates of advanced therapy use and colectomy were calculated. Predictors of advanced therapy use and colectomy within 5 years were analyzed and expressed as adjusted odds ratios (aORs) with 95% confidence intervals (CIs) after 1:1 propensity score matching (PSM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 15\u2005177 patients in the UC 5-ASA cohort (mean age 47.2\u2005\u00b1\u200519.1 years old, 49.2% female and 70.3% White), the 1-, 3- and 5-year incidence of advanced therapy use was 5.37%, 11.56% and 15.8%, respectively. After PSM, age\u2005&amp;lt;\u200540 years old (aOR 1.93, 95% CI, 1.73-2.15), male sex (aOR 1.13, 1.02-1.25), obesity (aOR 1.18, 95% CI, 1.05-1.31), pancolitis (aOR 1.18, 95% CI, 1.03-1.36), steroid use (aOR 1.79, 95% CI, 1.53-2.09), and CRP\u2005\u2265\u200512\u00a0mg\/L (aOR 1.39, 95% CI, 1.05-1.83) prior to 5-ASA initiation were associated with advanced therapy use within 5 years. The 1-, 3- and 5-year incidence of colectomy was 0.74%, 1.28%, and 1.64% respectively. After PSM, male sex (aOR 1.36, 95% 1.06-1.74), obesity (aOR 1.32, 95% CI, 1.02-1.69), primary sclerosing cholangitis (aOR 2.37, 95% CI, 1.11-5.06), pancolitis (aOR 1.90, 95% CI, 1.29-2.78), and steroid use (aOR 1.96, 95% CI, 1.35-2.84) were associated with colectomy within 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study provides updated estimates of advanced therapy utilization and colectomy as well as predictors of disease progression in patients with UC on 5-ASA in the biologic era.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf129","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T07:45:39Z","timestamp":1748504739000},"page":"3069-3076","source":"Crossref","is-referenced-by-count":6,"title":["Natural History, Treatment Persistence and Predictors of Treatment Failure in Patients With Ulcerative Colitis on 5-Aminosalicylic Acid: A US Population-Level Cohort Study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-2760","authenticated-orcid":false,"given":"Gursimran S","family":"Kochhar","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network , Pittsburgh, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himsikhar","family":"Khataniar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Allegheny Health Network , Pittsburgh, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana G","family":"Hashash","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Jacksonville, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7681-8111","authenticated-orcid":false,"given":"Miguel","family":"Regueiro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A","family":"Farraye","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic , Jacksonville, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6604-7712","authenticated-orcid":false,"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network , Pittsburgh, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"issue":"27","key":"2025112116470342900_CIT0001","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med."},{"issue":"8","key":"2025112116470342900_CIT0002","doi-asserted-by":"publisher","first-page":"CD000543","DOI":"10.1002\/14651858.CD000543.pub5","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","volume":"8","author":"Murray","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"2025112116470342900_CIT0003","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1586\/ecp.12.2","article-title":"Mesalamine in the treatment and maintenance of remission of ulcerative colitis","volume":"5","author":"Ham","year":"2012","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"2025112116470342900_CIT0004","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12876-017-0604-y","article-title":"Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study","volume":"17","author":"Nagahori","year":"2017","journal-title":"BMC Gastroenterol."},{"issue":"5","key":"2025112116470342900_CIT0005","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1053\/j.gastro.2021.09.077","article-title":"The future of precision medicine to predict outcomes and control tissue remodeling in inflammatory bowel disease","volume":"162","author":"Lamb","year":"2022","journal-title":"Gastroenterology."},{"issue":"2","key":"2025112116470342900_CIT0006","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/ecco-jcc\/jjy154","article-title":"Natural disease course of ulcerative colitis during the first five years of follow-up in a European Population-Based Inception Cohort-an Epi-IBD study","volume":"13","author":"Burisch","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"8","key":"2025112116470342900_CIT0007","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1177\/2050640619854277","article-title":"Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study","volume":"7","author":"Marti-Aguado","year":"2019","journal-title":"United European Gastroenterol J"},{"issue":"117","key":"2025112116470342900_CIT0008","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/MCG.0b013e3182431d56","article-title":"Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate","volume":"59","author":"Lee","year":"2012","journal-title":"Hepatogastroenterology."},{"issue":"3","key":"2025112116470342900_CIT0009","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.crohns.2010.12.011","article-title":"Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids","volume":"5","author":"Bello","year":"2011","journal-title":"J Crohns Colitis."},{"issue":"3","key":"2025112116470342900_CIT0010","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.dld.2011.10.004","article-title":"Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids","volume":"44","author":"Garcia-Planella","year":"2012","journal-title":"Dig Liver Dis."},{"issue":"4","key":"2025112116470342900_CIT0011","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000253850","article-title":"Do patients with ulcerative colitis diagnosed at a young age have more severe disease activity than patients diagnosed when older","volume":"81","author":"Lee","year":"2010","journal-title":"Digestion."},{"issue":"8","key":"2025112116470342900_CIT0012","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/apt.14268","article-title":"Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in \u00d6rebro, Sweden, 19632010","volume":"46","author":"Eriksson","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"2025112116470342900_CIT0013","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/ecco-jcc\/jjv129","article-title":"Disease outcome of ulcerative colitis in an era of changing treatment strategies: results from the Dutch population-based IBDSL cohort","volume":"9","author":"Jeuring","year":"2015","journal-title":"J Crohns Colitis."},{"issue":"11","key":"2025112116470342900_CIT0014","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1080\/00365521.2016.1200141","article-title":"Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden [ICURE] diagnosed during 2005\u20132009","volume":"51","author":"R\u00f6nnblom","year":"2016","journal-title":"Scand J Gastroenterol."},{"issue":"4","key":"2025112116470342900_CIT0015","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/00365520802600961","article-title":"Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)","volume":"44","author":"Solberg","year":"2009","journal-title":"Scand J Gastroenterol."},{"issue":"2","key":"2025112116470342900_CIT0016","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1053\/j.gastro.2006.11.015","article-title":"Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years","volume":"132","author":"Hoie","year":"2007","journal-title":"Gastroenterology."},{"issue":"6","key":"2025112116470342900_CIT0017","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/apt.12873","article-title":"The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study","volume":"40","author":"Reich","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"issue":"12","key":"2025112116470342900_CIT0018","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/ajg.2012.333","article-title":"Decreasing colectomy rates for ulcerative colitis: a population-based time trend study","volume":"107","author":"Kaplan","year":"2012","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"2025112116470342900_CIT0019","doi-asserted-by":"publisher","first-page":"e41120","DOI":"10.7759\/cureus.41120","article-title":"Advancements in inflammatory bowel disease: a narrative review of diagnostics, management, epidemiology, prevalence, patient outcomes, quality of life, and clinical presentation","volume":"15","author":"Muzammil","year":"2023","journal-title":"Cureus."},{"key":"2025112116470342900_CIT0020","article-title":"Tofacitinib. [Updated 2023 Jul 3]","volume-title":"StatPearls.","author":"Padda","year":"2024"},{"key":"2025112116470342900_CIT0021","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.2147\/IJGM.S433636","article-title":"Comprehensive review of ustekinumab utilization in inflammatory bowel diseases: insights from the ClinicalTrials.gov registry","volume":"16","author":"Alorfi","year":"2023","journal-title":"Int J Gen Med"},{"issue":"1","key":"2025112116470342900_CIT0022","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/01.MIB.0000437498.14804.50","article-title":"Patient preferences for surgical versus medical therapy for ulcerative colitis","volume":"20","author":"Bewtra","year":"2014","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"2025112116470342900_CIT0023","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1002\/ibd.21607","article-title":"Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002\u20132006","volume":"17","author":"Lakatos","year":"2011","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2025112116470342900_CIT0024","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/ecco-jcc\/jju016","article-title":"Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies","volume":"9","author":"Dias","year":"2015","journal-title":"J Crohns Colitis."},{"issue":"8","key":"2025112116470342900_CIT0025","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1097\/MIB.0000000000001211","article-title":"Clinical predictors of the risk of early colectomy in ulcerative colitis: a population-based study","volume":"23","author":"Al-Darmaki","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"2025112116470342900_CIT0026","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.3390\/biomedicines11123256","article-title":"The impact of obesity on inflammatory bowel disease","volume":"11","author":"Kaazan","year":"2023","journal-title":"Biomedicines"},{"issue":"11","key":"2025112116470342900_CIT0027","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1136\/gut.2007.146357","article-title":"C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study","volume":"57","author":"Henriksen","year":"2008","journal-title":"Gut."},{"key":"2025112116470342900_CIT0028","doi-asserted-by":"publisher","first-page":"1043412","DOI":"10.3389\/fmed.2022.1043412","article-title":"Predictive models for endoscopic disease activity in patients with ulcerative colitis: practical machine learning-based modeling and interpretation","volume":"9","author":"Li","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2025112116470342900_CIT0029","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/jcm9010094","article-title":"Ulcerative colitis: current and emerging treatment strategies","volume":"9","author":"Kayal","year":"2019","journal-title":"J Clin Med"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf129\/63570962\/izaf129.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/11\/3069\/63570962\/izaf129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/11\/3069\/63570962\/izaf129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T21:47:07Z","timestamp":1763761627000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/11\/3069\/8172978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf129","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,24]]}}}